The MyGenera™ platform, with its unique mechanism of action, is applicable to all therapeutic areas where it is possible to intervene by silencing the individual genes responsible for the disease.
The innovation of
Development of gene-specific oligonucleotide drugs
Reduced drug identification times compared to conventional methods
Improved drug efficacy
Reduced or absent therapy toxicity
Gene-specific therapies and their mechanism of action
The new class of gene-specific oligonucleotide drugs (Ag-PNA) is characterized by a short sequence of chemically modified DNA that acts on a single pathological target gene.
01
The gene-specific molecule
Target gene (two copies per cell)
The gene-specific molecule is an oligonucleotide that inhibits the activity of a target gene (by blocking mRNA transcription).
02
The mechanism
mRNA (thousands of copies)
The gene-specific oligonucleotide acts by selectively and strongly binding to a strand of the complementary DNA sequence contained in the target gene. The binding occurs on a strand of the open structure of the active target gene’s DNA, thereby blocking its transcription.
03
Applications
Protein (thousands of copies)
The unique mechanism of action of the MyGeneraTM platform is applicable to all therapeutic areas where it is possible to act by silencing the individual genes responsible for the disease.
English 
Italian